We will try to explain that academical trials has a lot of limitations in relation to regulation because regulation is defining for most of the commercial approaches, like the conventional drugs and cell therapy. It’s an important new aspect that need a more, an easier way to develop. Because if we need to follow all the elements that we have to follow by the regulations, finally, and only those approaches that can be used only for big number of patients will really arrive to these patients...
We will try to explain that academical trials has a lot of limitations in relation to regulation because regulation is defining for most of the commercial approaches, like the conventional drugs and cell therapy. It’s an important new aspect that need a more, an easier way to develop. Because if we need to follow all the elements that we have to follow by the regulations, finally, and only those approaches that can be used only for big number of patients will really arrive to these patients. When we try to develop immunotherapy, we try to find very specific approaches and probably without some kind of changes in regulation. It will be regulatory, those will be very difficult to obtain the final approval for specific targeting or specific patients that have a low level or a very low number of patients.